Get started
Live feed
·
PRReleasevia Quantisnow
Dicerna Pharmaceuticals, Inc. logo

Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria

ByQuantisnow·Wall Street's wire, on your screen.
DRNADicerna Pharmaceuticals, Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DRNA (Dicerna Pharmaceuticals, Inc.) and more on Quantisnow.